The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen.

ABSTRACT: Traditional vaccine development to prevent some of the worst current pandemic diseases has been unsuccessful so far. Germline-targeting immunogens have potential to prime protective antibodies (Abs) via more targeted immune responses. Success of germline-targeting vaccines in humans will depend on the composition of the human naive B cell repertoire, including the frequencies and affinities of epitope-specific B cells. However, the human naive B cell repertoire remains largely undefined. Assessment of antigen-specific human naive B cells among hundreds of millions of B cells from multiple donors may be used as pre-phase 1 ex vivo human testing to potentially forecast B cell and Ab responses to new vaccine designs. VRC01 is an HIV broadly neutralizing Ab (bnAb) against the envelope CD4-bind

SUBMITTER: Havenar-Daughton C 

PROVIDER: S-EPMC6145074 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature